Evaluation Of Interleukin-17 Level Among Sudanese Hepatitis B Patients In Khartoum State

Abstract

HBV remains a major global pathogen that cause acute and chronic hepatitis , liver cirrhosis , and hepatocellular carcinoma, IL-17 is pro-inflammatory cytokines play an important role in regulation of viral infections . This case-control study was aimed to evaluate the Interleukin-17(IL-17) level in Sudanese patients infected with Hepatitis B virus(HBV) compared to healthy control group in Khartoum state during period from March to October 2019. Sixty subjects, selected randomly in this study, with age varies from 17-50 years , 30 subjects are hepatitis B patients as case group with mean of age 29.7±9.57 years and 30 subjects as control group with mean of age 32.4±9.5 years are age and sex matched healthy control group. Three milliliter of Venous blood sample were collected in EDTA container from each subjects and separated using centrifuge to obtain plasma. IL-17 concentration was measured by Enzyme Linked Immunosorbent Assay (ELISA) in Ibn Sina University research center. The data was analyzed using statistical package of social science programme (Version 20) . students T test and one way ANOVA test were used to compare between means. P.value significant when ≤0.05 . Mean level of IL-17 was significantly increased in HBV patients (16.28± 9.57pg/ml) when compared to control group (7.47±8.48 pg/ml) with (p.value 0.00). mean level of IL-17 in hepatitis B patients was lower in males than females, which is statistically insignificant p.value 0.328 , and in healthy control IL-17 mean level was higher in female than male , which is statistically significant (P.value 0.017). Also, there was no statistically difference between IL-17 level in acute and chronic hepatitis B patients( P.value 0.223). Mean of IL-17 in patients who had didn't use treatment was higher than patients who used treatment with insignificant statistical correlation (P. value was 0.673). According to jaundice: there was no significant difference in IL-17 level between patients with symptoms of jaundice and patients have no symptoms of jaundice (p. value 0.854).